Arena Scores EMDAC Vote for Lorcaserin, Expanded Contract
The second time proved to be a charm for Arena Pharmaceuticals Inc.'s lorcaserin as it sought a vote of confidence from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) in its benefit-risk profile as a weight-loss drug.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST